Technical Analysis for ACAD - ACADIA Pharmaceuticals Inc.

Grade Last Price % Change Price Change
F 21.46 -3.46% -0.77
ACAD closed down 3.46 percent on Friday, July 23, 2021, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: Aug 3
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical ACAD trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -3.46%
50 DMA Resistance Bearish -3.46%
Expansion Pivot Sell Setup Bearish Swing Setup -3.46%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -3.46%
Older End-of-Day Signals for ACAD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


ACADIA Pharmaceuticals Inc. Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by pimavanserin, which is in Phase III development stage for the treatment of Parkinson's disease psychosis. It is also developing pimavanserin that has completed Phase II co-therapy trials for the treatment of schizophrenia; and is in Phase II clinical trials for the treatment of Alzheimer's disease psychosis. In addition, the company, through collaboration with Allergan, Inc., is developing alpha adrenergic agonists, which are in Phase II clinical trials for the treatment of chronic pain; and muscarinic agonist that is in Phase I clinical trials for the treatment of glaucoma. Further, it is developing two advanced preclinical programs directed at Parkinson's disease and other neurological disorders. The company was formerly known as Receptor Technologies, Inc. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pharmaceutical Industry Medication Chemical Compounds Alzheimer's Disease Parkinson's Disease Schizophrenia Neurological Disorders Chronic Pain Nervous System Disorders Central Nervous System Disorders Glaucoma Urological Disorders Treatment Of Parkinson's Disease Treatment Of Chronic Pain Treatment Of Alzheimer's Disease Treatment Of Glaucoma Treatment Of Schizophrenia Psychosis Muscarinic Agonist

Is ACAD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 57.46
52 Week Low 19.2
Average Volume 1,626,632
200-Day Moving Average 37.47
50-Day Moving Average 23.83
20-Day Moving Average 23.87
10-Day Moving Average 23.27
Average True Range 1.04
ADX 14.62
+DI 15.99
-DI 29.17
Chandelier Exit (Long, 3 ATRs) 23.19
Chandelier Exit (Short, 3 ATRs) 24.44
Upper Bollinger Bands 25.81
Lower Bollinger Band 21.92
Percent B (%b) -0.12
BandWidth 16.27
MACD Line -0.48
MACD Signal Line -0.23
MACD Histogram -0.2419
Fundamentals Value
Market Cap 3.41 Billion
Num Shares 159 Million
EPS -1.97
Price-to-Earnings (P/E) Ratio -10.92
Price-to-Sales 19.85
Price-to-Book 12.93
PEG Ratio -0.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.84
Resistance 3 (R3) 22.95 22.59 22.61
Resistance 2 (R2) 22.59 22.24 22.54 22.53
Resistance 1 (R1) 22.03 22.02 21.85 21.92 22.46
Pivot Point 21.67 21.67 21.59 21.62 21.67
Support 1 (S1) 21.11 21.32 20.93 21.00 20.46
Support 2 (S2) 20.75 21.10 20.70 20.39
Support 3 (S3) 20.19 20.75 20.31
Support 4 (S4) 20.08